TY - JOUR
T1 - Recombinant luteinizing hormone supplementation in assisted reproductive technology
T2 - a systematic review
AU - Alviggi, Carlo
AU - Conforti, Alessandro
AU - Esteves, Sandro C.
AU - Andersen, Claus Yding
AU - Bosch, Ernesto
AU - Bühler, Klaus
AU - Ferraretti, Anna Pia
AU - De Placido, Giuseppe
AU - Mollo, Antonio
AU - Fischer, Robert
AU - Humaidan, Peter
AU - International Collaborative Group for the Study of r-hLH (iCOS-LH)
PY - 2018
Y1 - 2018
N2 - Objective: To assess the role of recombinant human LH (r-hLH) supplementation in ovarian stimulation for ART in specific subgroups of patients. Design: Systematic review. Setting: Centers for reproductive care. Patient(s): Six populations were investigated: 1) women with a hyporesponse to recombinant human FSH (r-hFSH) monotherapy; 2) women at an advanced reproductive age; 3) women cotreated with the use of a GnRH antagonist; 4) women with profoundly suppressed LH levels after the administration of GnRH agonists; 5) normoresponder women to prevent ovarian hyperstimulation syndrome; and 6) women with a “poor response” to ovarian stimulation, including those who met the European Society for Human Reproduction and Embryology Bologna criteria. Intervention(s): Systematic review. Main Outcome Measure(s): Implantation rate, number of oocytes retrieved, live birth rate, ongoing pregnancy rate, fertilization rate, and number of metaphase II oocytes. Result(s): Recombinant hLH supplementation appears to be beneficial in two subgroups of patients: 1) women with adequate prestimulation ovarian reserve parameters and an unexpected hyporesponse to r-hFSH monotherapy; and 2) women 36–39 years of age. Indeed, there is no evidence that r-hLH is beneficial in young (<35 y) normoresponders cotreated with the use of a GnRH antagonist. The use of r-hLH supplementation in women with suppressed endogenous LH levels caused by GnRH analogues and in poor responders remains controversial, whereas the use of r-hLH supplementation to prevent the development of ovarian hyperstimulation syndrome warrants further investigation. Conclusion(s): Recombinant hLH can be proposed for hyporesponders and women 36–39 years of age.
AB - Objective: To assess the role of recombinant human LH (r-hLH) supplementation in ovarian stimulation for ART in specific subgroups of patients. Design: Systematic review. Setting: Centers for reproductive care. Patient(s): Six populations were investigated: 1) women with a hyporesponse to recombinant human FSH (r-hFSH) monotherapy; 2) women at an advanced reproductive age; 3) women cotreated with the use of a GnRH antagonist; 4) women with profoundly suppressed LH levels after the administration of GnRH agonists; 5) normoresponder women to prevent ovarian hyperstimulation syndrome; and 6) women with a “poor response” to ovarian stimulation, including those who met the European Society for Human Reproduction and Embryology Bologna criteria. Intervention(s): Systematic review. Main Outcome Measure(s): Implantation rate, number of oocytes retrieved, live birth rate, ongoing pregnancy rate, fertilization rate, and number of metaphase II oocytes. Result(s): Recombinant hLH supplementation appears to be beneficial in two subgroups of patients: 1) women with adequate prestimulation ovarian reserve parameters and an unexpected hyporesponse to r-hFSH monotherapy; and 2) women 36–39 years of age. Indeed, there is no evidence that r-hLH is beneficial in young (<35 y) normoresponders cotreated with the use of a GnRH antagonist. The use of r-hLH supplementation in women with suppressed endogenous LH levels caused by GnRH analogues and in poor responders remains controversial, whereas the use of r-hLH supplementation to prevent the development of ovarian hyperstimulation syndrome warrants further investigation. Conclusion(s): Recombinant hLH can be proposed for hyporesponders and women 36–39 years of age.
KW - ART
KW - IVF/ICSI
KW - Luteinizing hormone (LH)
KW - ovarian stimulation
KW - recombinant LH
U2 - 10.1016/j.fertnstert.2018.01.003
DO - 10.1016/j.fertnstert.2018.01.003
M3 - Journal article
C2 - 29653717
AN - SCOPUS:85045076149
SN - 1546-2501
VL - 109
SP - 644
EP - 664
JO - Sexuality, Reproduction and Menopause
JF - Sexuality, Reproduction and Menopause
IS - 4
ER -